Go behind the scenes of LogiPharma USA 2026 with program director Charleen Ring and McKesson's Chris Van Norman in this Pharma Pulse special.
Commentary|Podcasts|January 29, 2026
Pharma Pulse: AI’s $120M Cardiometabolic Play
Author(s)Nicholas Saraceno, Senior Editor
In today’s Pharma Pulse, the AAP defies federal vaccine cuts, Morris & Dickson scales its specialty footprint, and Insilico Medicine targets cardiometabolic health with a new partnership.
Advertisement
Welcome to Pharma Pulse, a Pharmaceutical Commerce podcast where we bring you the latest insights shaping patient access, supply chain/logistics, data & tech, and healthcare innovation. I’m your host, and let’s get into today’s headlines.
- First, the American Academy of Pediatrics has released their own
2026 vaccine schedule in direct response to the recent HHS overhaul. While federal guidelines moved six routine vaccines to shared decision-making, the AAP is re-endorsing all 18 immunizations for US children. - In supply chain news, Morris & Dickson has
officially acquired Prodigy Health. This significantly boosts the distributor’s reach into high-cost plasma-derived therapies and specialty care settings. - Lastly, Insilico Medicine has inked a
$120 million deal with Qilu Pharmaceuticals. The company will be using Insilico’s Pharma.AI platform to design novel small molecules, aiming to slash discovery timelines for cardiometabolic diseases.
That’s it for this episode of Pharma Pulse. For more insights on trends transforming pharmaceutical access and care delivery, visit
Thanks for listening—until next time, stay well and stay informed.
You can catch Pharma Pulse directly on
Advertisement
Related to this article
In this week's Pharma Pulse, Arkansas independent pharmacies bring an underpayment suit against Express Scripts, Novo Nordisk taps Anthropic for AI-driven drug discovery, and Sanofi, UCB and Opella join AstraZeneca on a supply chain heat decarbonization program.
In this week's Pharma Pulse, DHL breaks ground on a new cold chain hub at Singapore's Changi Airport, a new report finds pharma's commercial model in the middle of a fundamental reset, and the FDA grants accelerated approval to sevabertinib.
Twenty-six manufacturers now hold most-favored-nation agreements, and the commitments attached to the pricing terms may matter more than the prices themselves.
AI-native operating systems present new capabilities to improve pharma supply chain operations.
In this week's Pharma Pulse, nine more drugmakers join the MFN program, GoodRx adds a family plan, IPC formalizes its USave partnership, and CSafe expands its thermal cover offerings.
The acquisition formalizes a nearly decade-old partnership as independent pharmacies lean on cooperatives to offset PBM reimbursement pressure and closures.
Cencora's Ameer Ali on the operational lift behind the 12-digit NDC shift, the readiness gap across manufacturers and what's at stake for product flow if systems aren't ready in time.
Advertisement
Advertisement